Chronic hepatitis B seems to progress faster in men, report scientists

NewsGuard 100/100 Score

Scientists in China are reporting discovery of unusual liver proteins, found only in males, that may help explain the long-standing mystery of why the hepatitis B virus (HBV) sexually discriminates -- hitting men harder than women. Their study has been published online in ACS' Journal of Proteome Research, a monthly publication.

Shuhan Sun, Fang Wang and colleagues note that chronic hepatitis B seems to progress and cause liver damage faster in men, with men the main victims of the virus's most serious complications -- cirrhosis and liver cancer. Men infected with HBV also are 6 times more likely than women to develop a chronic form of the disease. About 400 million people worldwide have chronic hepatitis B, including a form that is highly infectious and can be transmitted through blood, saliva, and sexual contact.

In experiments with laboratory mice, the scientists found abnormal forms of apolipoprotein A-I (Apo A-I), a protein involved in fighting inflammation, in the livers of infected male mice but not infected females. They then identified abnormal forms of these Apo A-I proteins in blood of men infected with HBV, but not in women. In addition to explaining the gender differences, the proteins may provide important markers for tracking the progression of hepatitis B, the scientists suggest.

Source: American Chemical Society

Comments

  1. Anastasia Anastasia United States says:

    Alpha-interferons are known to be the first drugs in the US that have been approved for treating Chronic Hepatitis B. An Interferon treatment is usually recommended in the case of patients who have the "replicative disease" (a.k.a. HBeAg positive). About 40 percent of such patients will lose the HBeAg serum after 16 weeks of intense treatment with the Interferon-alpha drug. The loss of HBeAg can be correlated with a prognosis which is improved. A few patients who are treated (less than 10%) can even be cured by this. Patients who are treated with the Interferon-alpha drug should present clear evidence of an infection with the virus that causes this disorder. Furthermore, the presence of Chronic Hepatitis B surface antigen in the patient’s blood ought to be documented for about six months. The individuals should also detain virus replication evidence, which can be documented the presence in the patient’s blood of the hepatitis B e antigen. Ongoing liver inflammation may also be present. A biopsy of the liver must also be done before treatment. Patients who have severe and decompensated disease of the liver (for example encephalopathy, very high serum bilirubin, ascites, prolonged prothrombin time) must not be allowed to follow a treatment that implies the intake of the Alfa Interferon.

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
New optimized vaccine approach targets Hepatitis C virus variability